• WedgeWPP IS the fresh global Innovative Medicine media incumbent since Dec 2024 — DEFEND + EXPAND pitch. CMI Media + GroupM + Mindshare hold scope.
• WhyUser brief said 'J&J pharma media Omnicom OMD' — OUTDATED. J&J moved global media from IPG's J3 to WPP/GroupM Dec 2024 — $300M US/Canada win including J&J Innovative Medicine (formerly Janssen). WPP also runs CMI Media (healthcare specialist) on the account.
• Who ·

1. W1WPP IS the fresh global Innovative Medicine media incumbent since Dec 2024 — DEFEND + EXPAND pitch. CMI Media + GroupM + Mindshare hold scope.
2. W2TW oncology + immunology HCP programs — defend WPP scope locally
3. W3ACUVUE TW consumer marketing is separate scope — opportunity to pitch consumer side (youth digital, optician channel, Z-gen)
4. W4MedTech TW (orthopedics, surgical) — separate from Innovative Medicine, may have agency latitude
5. W5Don't pitch Kenvue under J&J — Kenvue is a separate legal entity and different AOR (Publicis media, WPP creative ex-Neutrogena)
6. W6Local TW oncology + rare-disease patient-support programs — culturally specific family-decision marketing wedge

• User brief said 'J&J pharma media Omnicom OMD' — OUTDATED. J&J moved global media from IPG's J3 to WPP/GroupM Dec 2024 — $300M US/Canada win including J&J Innovative Medicine (formerly Janssen). WPP also runs CMI Media (healthcare specialist) on the account.
• User brief said 'Kenvue media WPP/EssenceMediacom' — ALSO OUTDATED. Dec 2025 Kenvue review: WPP wins creative (all brands except Neutrogena); Publicis takes media + commerce + tech + Neutrogena creative. Kenvue media is PUBLICIS not WPP.
• WPP is the BIG winner on J&J Innovative Medicine (pharma) globally since Dec 2024 — this is a fresh defend/grow opportunity. Mindshare + CMI Media Group + other WPP units jointly service.
• Kenvue (J&J Consumer spin-off 2023 → NYSE: KVUE) is now legally separate from J&J — should be tracked separately as a distinct account.
• Kenvue global media spend ~$1.35B (2025). Publicis just won this — WPP has creative only (ex-Neutrogena).
• J&J MedTech (orthopedics, surgery, ACUVUE, vision care) is its own division with separate agency relationships — not unified with Innovative Medicine.
• ACUVUE consumer marketing in TW is youth/digital-heavy — separate from Rx and B2B MedTech scopes.

• Miyuki OgushiManaging Director, Janssen Taiwan (J&J Innovative Medicine)

  since unknown

  Leads J&J Innovative Medicine (formerly Janssen) Taiwan — oncology, immunology, neuroscience, infectious disease, cardiovascular & metabolic, pulmonary hypertension. Cited in 2023 AmCham TOPICS on healthcare innovation.

  Source ↗
• Louis Ko (legacy)Taiwan General Manager, Johnson & Johnson Medical (MedTech) — historical

  since pre-2019

  Historical reference from Kellogg alumni interview (2019). Current MedTech TW GM may differ — included as anchor.

  Source ↗

J&J post-2023 = Innovative Medicine (pharma) + MedTech (devices, vision, surgery) only. Consumer Health spun off as Kenvue (separate company NYSE: KVUE) in 2023. J&J Innovative Medicine TW is HCP-channel-led (oncology, immunology, neuroscience, infectious disease). MedTech TW is B2B surgeon/specialist-led. ACUVUE consumer is the most consumer-facing surface. WPP is fresh global media incumbent on Innovative Medicine since Dec 2024.

• J&J Innovative Medicine oncology HCP programs2024 · WPP (CMI Media + GroupM) post-Dec 2024 US/Canada win · HCP-led + patient support

  Lung cancer (rare mutations), blood cancer, pulmonary hypertension — flagship TW Rx scope. HCP-channel by regulation.

  Source ↗
• J&J MedTech orthopedic + surgical2024 · B2B / specialty surgery shops · HCP + KOL surgeon programs

  Orthopedics, surgery, vision (ACUVUE), neurovascular. TW HCP/surgeon-targeted marketing.

  Source ↗
• ACUVUE contact lens consumer2024 · Multi-shop (separate from Innovative Medicine scope) · Consumer + optician channel

  ACUVUE 1-Day, Oasys, MOIST — strong TW penetration. Optician channel + youth digital.

  Source ↗
• Kenvue (formerly J&J Consumer Health) — Listerine, Band-Aid, Neutrogena, Tylenol2025 · WPP creative (ex-Neutrogena) + Publicis media + Publicis creative for Neutrogena (Dec 2025 win) · Multi-brand consumer health

  Kenvue (NYSE: KVUE) spun off from J&J in 2023. Dec 2025 global review: WPP wins creative + production for all brands except Neutrogena; Publicis takes media + commerce + healthcare professional support + tech, plus creative for Neutrogena. Note: Kenvue is no longer J&J — separate stock_id.

  Source ↗

Don't conflate Kenvue with J&J — they are separate legal entities since 2023, separate AORs (Kenvue: Publicis media). Don't pitch as a challenger on Innovative Medicine globally — WPP is the fresh Dec 2024 incumbent. Don't ignore the MedTech vs Innovative Medicine split — they are separate scopes with different agency latitudes. Acknowledge HCP-channel restrictions in TW Pharmaceutical Affairs Act for Rx.

• GSK Taiwan (vaccines + Rx)
• Pfizer Taiwan (Rx + vaccines)
• Roche Taiwan (oncology — direct vs J&J oncology)
• Novartis Taiwan (immunology)
• MedTech competitors: Medtronic, Stryker, Zimmer Biomet, Alcon (vs ACUVUE)
• ACUVUE consumer competitors: Bausch + Lomb, Alcon Dailies, CooperVision

• ? Current J&J MedTech Taiwan GM name (Louis Ko was historical)
• ? Does Mindshare TW execute Innovative Medicine buying, or does it route through Mindshare APAC?
• ? ACUVUE TW agency — separate from Innovative Medicine scope?
• ? Future of Kenvue TW (separate stock_id needed): track Publicis media + WPP creative roll-out timing